Harm reduction – drugs

Evidence review summary: drug demand reduction, treatment, and harm reduction, 2017
This short report presents a brief overview of recent evidence for the most effective approaches in the fields of drug use prevention, drug use treatment and harm reduction. It discusses the strengths and limitations of the evidence and some challenges for the implementation of the approaches, and it summarises the principles underpinning the successful knowledge transfer that supports the use of evidence in the development and delivery of policy and practice | EMCDDA, Portugal

Still no harm reduction? A critical review of the UK Government’s new Drug Strategy (PDF), 2017
This briefing, endorsed by eight of the UK’s leading harm reduction and drug treatment organisations, looks at whether the focus on harm reduction has improved under the new Drug Strategy (2017), and discusses challenges in the funding environment which will have a disproportionate impact on harm reduction services | National AIDS Trust – secretariat to the English Harm Reduction Group, UK

Guidance: Widening the availability of naloxone, 2017
Naloxone is the emergency antidote for overdoses caused by heroin and other opiates/opioids (such as methadone and morphine) | DoH et al, UK

Take-home naloxone for opioid overdose in people who use drugs (PDF), 2017
Advice for local authorities and local partners on widening the availability of naloxone to reduce overdose deaths from heroin and other opiate drugs | PHE, UK

Global State of Harm Reduction 2016
Services to reduce drug-related harms are failing to keep up with growing need, despite pledges to combat AIDS among people who inject drugs | HRI, UK

Evaluation of the HSE Naloxone Demonstration Project (PDF), 2016
The HSE in conjunction with their partners[1] who were involved in the Naloxone Demonstration Project is marking International Overdose Awareness Day (IOAD) to raise awareness of the risks of drug overdose and the impact on individuals and their families [see also press release] | HSE, Ireland

Do no harm – Health, human rights and people who use drugs, 2016
In this report, UNAIDS shows what works to reduce the impact of HIV and other harms related to drug use. Countries that have moved away from laws and policies that are harmful to people who use drugs and that have increased investment in harm reduction have reduced new HIV infections and improved health outcomes. These policies also deliver broader social benefits, such as lower levels of drug-related crime and reduced pressure on health-care and criminal justice systems | UNAIDS, Switzerland

The Case for a Harm Reduction Decade, 2016 (PDF)
HIV-related deaths and new HIV infections among people who inject drugs could be almost entirely eliminated by 2030 with just a tiny shift in global drug control spending. This is one finding of our report | HRI, UK

Club Drug Use Among Lesbian, Gay, Bisexual and Trans (LGBT) People (PDF), 2016
This report has been written as part of the wider suite of clinical guidance and tools that aim to provide evidence-based knowledge to inform the management in clinical practice of harms related to the use of ‘club drugs’. It is a supplement to, and should be read in conjunction with, Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances (www.neptune-clinical-guidance.co.uk) | Neptune Project, UK

Preventing opioid overdose deaths with take-home naloxone, EMCDDA, 2016
This publication examines the case for distributing naloxone, an emergency medication, to people who inject opioids such as heroin and to others who might witness an opioid overdose | EMCDDA, Portugal

HIV, HCV, TB and Harm Reduction in Prisons,  2016
This report identifies some of the most important human rights and public health standards relating to HIV, HCV and TB in prisons, and the vital role of harm reduction provision in ensuring them | HRI, UK

Naloxone – preliminary advice from the working group updating Drug Misuse and Dependence: UK Guidelines on Clinical Management, 2015
The working group updating the 2007 national clinical guidelines on drug treatment has published some preliminary advice on naloxone before addressing its supply and use more fully in the published update next year. The advice covers naloxone dosing in overdose situations, take-home naloxone products that can be supplied and training that should be provided, now and following legislation to make naloxone more widely available from October 2015 onwards | PHE, UK

Road to Success: Towards Sustainable Harm Reduction Financing Regional report. First year of the Regional Program “Harm Reduction Works – Fund It!” (PDF)
This report analyses the current state of harm reduction investment and services for people who inject drugs in East Europe and Central Asia. Monitoring of harm reduction services and investments in harm reduction programs has been conducted within the Regional Program “Harm Reduction Works – Funded It!” being implemented by Eurasian Harm Reduction Network (EHRN) with financial support of the Global Fund to fight AIDS, tuberculosis and malaria | EHRN, Lithuania

Drug consumption rooms: an overview of provision and evidence, 2015
Supervised drug consumption facilities, where illicit drugs can be used under the supervision of trained staff, have been operating in Europe for the last three decades. These facilities primarily aim to reduce the acute risks of disease transmission through unhygienic injecting, prevent drug-related overdose deaths and connect high-risk drug users with addiction treatment and other health and social services. They also seek to contribute to a reduction in drug use in public places and the presence of discarded needles and other related public order problems linked with open drug scenes | EMCDDA, Portugal

Mortality among drug users is Europe – new and old challenges for public health, 2015
More than 6 000 drug users die of overdose each year in the European Union, and most of these deaths occur among problem drug users and involve opioids. In addition, many deaths related indirectly to drug use occur each year. To gain a clearer picture of the overall number of lives lost due to drug use in Europe, this paper builds on the results of an earlier work that looked at all-cause mortality among problem drug users | EMCDDA, Portugal

Global State of Harm Reduction 2014, Harm Reduction International, 2015
The data gathered for this report provides a critical baseline against which progress can be measured in terms of international, regional and national recognition of harm reduction in policy and practice | HRI, UK

Harm Reduction and the Global HIV Epidemic AmfAR, 2015 (PDF)
This report assesses the state of harm reduction worldwide by focusing on the steps that five sample countries—Kenya, Kyrgyzstan, Nigeria, Ukraine, and Vietnam—have, or have not, taken to address the HIV epidemic among people who inject drugs (PWID) | AmfAR, USA

The negative impact of drug control on public health, Global Commission on Drug Policy, 2015
This report considers the impact of current drug policy and aims to bring to the international level an informed, science-based discussion about humane and effective ways to reduce the harm caused by drugs to people and societies | GDP, Brazil

A Global Review of the Harm Reduction Response to Amphetamines: A 2015 Update
An assessment of international approaches to amphetamine harm reduction | HRI, UK

Harm reduction, evidence, impacts and challenges, 2010
The EMCDDA’s 10th scientific monograph, entitled Harm reduction: evidence, impacts and challenges provides a comprehensive overview of the harm reduction field | EMCDDA, Portugal